DRUG RESISTANCE RESTRICTS THE EFFICACY OF SHORT TERM LOW DOSE MITOMYCIN-C TREATMENT IN UMUC-3 BLADDER CANCER CELLS

Basit Öğe Kaydı
dc.contributor.authorGul, Murat
dc.contributor.authorGoktas, Serdar
dc.contributor.authorKars, Meltem Demirel
dc.contributor.authorKaynar, Mehmet
dc.date.accessioned2024-02-23T14:49:09Z
dc.date.available2024-02-23T14:49:09Z
dc.date.issued2018
dc.departmentNEÜen_US
dc.description.abstractOBJECTIVE: Mitomycin-c (MMC) is the most used intravesical adjuvant agent in non-muscle invasive bladder cancer to prevent recurrence. However, a consensus on about appropriate dosage and treatment schedule of MMC is lacking. We, therefore, aimed to evaluate the most appropriate MMC dosage using an in vitro model of high-grade human bladder cancer. METHODS: UMUC-3 cells, a model for high-grade bladder cancer, were exposed to MMC in different time courses to assess its toxicological effects. XTT cell proliferation kit was used to evaluate the effect of MMC on the proliferation of UMUC-3 cell line. Gene expression analysis for the MDR1, BCL2 and ANXA5 genes was performed by Real-time PCR and flow cytometry analysis were conducted to evaluate the cell death mechanism and acquired resistance after MMC exposure. An ANXA5 kit was used to detect apoptotic cells, and 7-AAD was used to detect necrotic cells. RESULTS: Cell proliferation was prevented to a large extent (IC50, 0.175-0.081 mg/mL) and cytotoxic effects were observed after 5 mu g/mL and 10 mu g/mL MMC administrations for 1 and 2-h, after the 4th and 2nd dose cycles, respectively. Moreover, cell death was observed at 5 mu g/mL and 10 mu/mL MMC applications for 1-h and 2-h by the sixth and second week, respectively. Flow cytometry exhibits increased subpopulation of drug-extruding UMUC-3 cells after a single dose of MMC for 1-h. MMC did not increase the number of apoptotic or necrotic cells; yet, MDR1 (multiple drug resistance) and ANXA5 (apoptotic) expression levels were increased and BCL2 (anti-apoptotic) expression was decreased. Limitations: In-vitro nature of the study and working with only one cell culture are inherit limitations of this project. CONCLUSION: A single dose of MMC administration for 1 or 2-h results in drug-resistance. If maintenance treatment is administered for one hour, it should be continued throughout a 6-week period.en_US
dc.description.sponsorshipSelcuk University, Scientific Research Projects (SUSRP) [13102031]en_US
dc.description.sponsorshipThis study was supported by Selcuk University, Scientific Research Projects (SUSRP) (project number: 13102031).en_US
dc.identifier.endpage793en_US
dc.identifier.issn0004-0614
dc.identifier.issn1576-8260
dc.identifier.issue9en_US
dc.identifier.pmid30403381en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage783en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12452/18027
dc.identifier.volume71en_US
dc.identifier.wosWOS:000457818300007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherIniestares, S.A.en_US
dc.relation.ispartofArchivos Espanoles De Urologiaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBladder Canceren_US
dc.subjectMulti-Drug Resistanceen_US
dc.subjectMitomycin-Cen_US
dc.subjectFlow Cytometryen_US
dc.subjectUmuc-3en_US
dc.titleDRUG RESISTANCE RESTRICTS THE EFFICACY OF SHORT TERM LOW DOSE MITOMYCIN-C TREATMENT IN UMUC-3 BLADDER CANCER CELLSen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu